Try our beta test site

flt3L in Treating Patients With Acute Myeloid Leukemia

This study has been completed.
National Cancer Institute (NCI)
Cancer and Leukemia Group B
Southwest Oncology Group
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: September 11, 2000
Last updated: June 20, 2013
Last verified: September 2006

RATIONALE: Drugs such as flt3L may stimulate a person's immune system and help kill cancer cells. It is not yet known if flt3L is effective in treating acute myeloid leukemia.

PURPOSE: Randomized phase III trial to determine the effectiveness of flt3L in treating patients who have acute myeloid leukemia that is in remission.

Condition Intervention Phase
Biological: recombinant flt3 ligand
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: July 2000
Study Completion Date: January 2007
Detailed Description:


  • Compare the failure-free survival and overall survival in patients with acute myeloid leukemia in complete remission treated with maintenance flt3 ligand vs observation alone.
  • Compare the long-term immunologic effects of these regimens in these patients.
  • Compare the long-term safety and toxicity of these regimens in these patients.

OUTLINE: This is a randomized study. Patients are stratified according to complete remission (CR) (first vs second vs third or subsequent) and post-remission therapy (yes vs no). Patients are randomized to one of two treatment arms.

  • Arm I: Patients receive flt3 ligand subcutaneously daily on days 1-14. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients undergo observation alone. Patients begin treatment or observation within 4 weeks after documentation of CR after induction therapy or within 4 weeks after discharge from hospital after post-remission therapy.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 139 patients will be accrued for this study within approximately 28 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of acute myeloid leukemia in first, second, third, or subsequent complete remission (CR)

    • Must be at least 60 years of age if first CR
    • Must have had histological proof (from bone marrow aspirate, smears, or touch preps of marrow biopsy) of one of the following prior to achieving CR:

      • Acute myeloblastic leukemia (M0, M1, M2)
      • Acute promyelocytic leukemia (M3)
      • Acute myelomonocytic leukemia (M4)
      • Acute monocytic leukemia (M5)
      • Acute erythroleukemia (M6)
      • Acute megakaryocytic leukemia (M7)
      • Refractory anemia with excess blasts in transformation



  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • Not specified


  • Bilirubin less than 3 times upper limit of normal (ULN)
  • SGOT less than 3 times ULN


  • Creatinine less than 2 mg/dL


  • No clinically significant active cardiac disease


  • No clinically significant active pulmonary disease


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No uncontrolled or active autoimmune disease


Biologic therapy:

  • Prior autologous bone marrow transplantation (BMT) allowed
  • No prior allogeneic BMT
  • Other prior immunotherapy allowed if not received during the most recent treatment


  • Not specified

Endocrine therapy:

  • Not specified


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00006223

  Show 47 Study Locations
Sponsors and Collaborators
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Cancer and Leukemia Group B
Southwest Oncology Group
Study Chair: Jacob M. Rowe, MD Rambam Health Care Campus
Study Chair: Richard A. Larson, MD University of Chicago
Study Chair: John E. Godwin, MD, MS Loyola University
  More Information Identifier: NCT00006223     History of Changes
Other Study ID Numbers: CDR0000068143
Study First Received: September 11, 2000
Last Updated: June 20, 2013

Keywords provided by National Cancer Institute (NCI):
adult acute myeloid leukemia in remission
adult acute erythroid leukemia (M6)
adult acute myeloblastic leukemia without maturation (M1)
adult acute myeloblastic leukemia with maturation (M2)
adult acute promyelocytic leukemia (M3)
adult acute myelomonocytic leukemia (M4)
adult acute monoblastic leukemia (M5a)
adult acute megakaryoblastic leukemia (M7)
adult acute monocytic leukemia (M5b)
adult acute minimally differentiated myeloid leukemia (M0)

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Flt3 ligand protein
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Radiation-Protective Agents
Protective Agents processed this record on March 29, 2017